Buprenorphine's Medicaid Footprint Reveals Exactly Where Addiction Care Fails
Medicaid spent $1,340.91 per enrollee on buprenorphine-related treatment in Alaska. In Virginia, it spent $86.83. Those two numbers, from the same federal program, describe a 15-fold gap in addiction care investment that has nothing to do with the severity of the opioid crisis and everything to do with how states have chosen to structure access.
A 15-Fold Gap That Maps Onto Structural Failure
The spending distribution across the 20 states in this dataset is not a gentle gradient. It's a cliff. Alaska and Vermont sit at $1,340.91 and $856.17 per enrollee respectively, followed by Rhode Island at $484.90 and Connecticut at $391.15. Then the numbers drop fast. New York, the state with the largest total Medicaid spending on buprenorphine at $983,991,115, lands at just $131.41 per enrollee across 7.5 million enrollees. Virginia, at the bottom, reaches $86.83.
| State | Spending Per Enrollee | Total Spending |
|---|---|---|
| Alaska | $1,340.91 | $258,452,970 |
| Vermont | $856.17 | $167,892,917 |
| Rhode Island | $484.90 | $165,118,538 |
| Connecticut | $391.15 | $383,724,850 |
| Massachusetts | $333.46 | $648,425,005 |
| New York | $131.41 | $983,991,115 |
| Ohio | $100.62 | $325,896,246 |
| Virginia | $86.83 | $164,709,652 |
Per-enrollee spending matters more than total spending because it reflects actual access. New York's nearly $1 billion in total outlays looks substantial until you divide it across 7.5 million Medicaid enrollees and realize each one is backed by roughly the same investment as a single copay. Vermont, with 196,098 enrollees and $167,892,917 in total spending, is delivering a fundamentally different level of treatment infrastructure to its population. For patients in low-spending states, the gap isn't abstract: it translates directly into fewer covered treatment slots, fewer providers willing to accept Medicaid, and longer waits for medication that reduces overdose mortality.
Where the Money Actually Flows: Organizations, Not Clinicians
Every single provider among the top 20 billers in this dataset is an organization-type entity. Not one individual clinician appears. Hartford Dispensary in Connecticut submitted 10,456,756 claims totaling $118,983,424 under HCPCS code H0020, making it the single largest biller by volume. HABIT OPCO, LLC in Springfield, Massachusetts submitted 8,407,460 claims under H0020 and an additional 501,156 claims under G2067, for a combined total exceeding $175 million across both codes.
The California county health departments tell a similar story. Los Angeles County Department of Public Health billed 7,019,424 claims for $103,024,306. County of San Diego billed 1,362,125 claims for $67,927,899. These are government agencies and large treatment organizations absorbing the overwhelming majority of Medicaid volume.
The outlier that clarifies the pattern: Southeast Alaska Regional Health Consortium in Juneau submitted just 46,816 claims but received $39,924,332, the highest payment-per-claim ratio among all top providers. That's a very different delivery model from Hartford Dispensary's 10 million claims, and it helps explain why Alaska's per-enrollee spending is so high. Fewer, more intensive encounters rather than high-volume outpatient dispensing.
The Absence of Solo Practitioners Is the Finding
The complete absence of individual providers from the top 20 billers raises a structural question that the spending data alone can't resolve but clearly frames. Buprenorphine prescribing by office-based physicians was, for years, the policy model: train primary care doctors, issue waivers, integrate addiction treatment into mainstream medicine. The claims data suggests that model has not translated into high-volume Medicaid billing. Organizations, not individual practitioners, are carrying the load.
This matters for the low-spending states. Virginia at $86.83 per enrollee and Ohio at $100.62 are not small states with small Medicaid programs. Ohio has 3.2 million Medicaid enrollees. If the organizational infrastructure for high-volume buprenorphine billing simply doesn't exist in those states at scale, the per-enrollee spending gap won't close by encouraging more individual physicians to prescribe. It would require building the same kind of institutional capacity that Connecticut, Vermont, and Massachusetts have already built.
Whether the 15-fold variation between Alaska and Virginia represents 15 times more treatment delivered, or 15 times more infrastructure to deliver it, the patients on the low end of that ratio are the ones absorbing the difference.
Ask a follow-up
Run one of these against the same data. The question is filled in for you.
- Which states have the highest total Medicaid spending on buprenorphine-related HCPCS codes (H0020, G2067) per year from 2018 to 2024?
- What are the top 20 organizations by total Medicaid buprenorphine spending, and what is their average payment per claim?
- How many buprenorphine-prescribing clinicians (e.g., addiction medicine, psychiatry) are enrolled in Medicare in Virginia vs. Vermont?
Explore the data yourself
Run your own queries against 240M+ rows of federal health data using natural language — powered by AI.
Start analyzing